RxDoctor Payments Data

Louis Malinow, MD

Internal Medicine · Baltimore, MDNPI 1225007925

Payments from drug & device makers

$212in general payments, 2019–2025

Across 13 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$66
  • GSK$31
  • Astellas Pharma US Inc$28
  • AbbVie$20
  • Boehringer Ingelheim$19
  • Novartis$16
  • plus $32 from 3 others

What the payments were for

  • Food & beverage$19291%
  • Education$209%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$212 in reported general payments places this provider in the 50th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$142,049
Medicare patients
217
Services billed
3,400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin111$135,900
EliquisApixaban76$95,686
MounjaroTirzepatide83$91,570
OzempicSemaglutide32$72,143
TrulicityDulaglutide37$47,402
Repatha SureclickEvolocumab51$45,635
MyrbetriqMirabegron39$32,372
XareltoRivaroxaban28$26,792
Praluent PenAlirocumab18$22,867
FarxigaDapagliflozin Propanediol20$21,180
Tresiba Flextouch U-100Insulin Degludec41$20,567
Xigduo XrDapaglifloz Propaned/Metformin15$17,797
EntrestoSacubitril/Valsartan17$16,151
Ezetimibe318$14,550
Rosuvastatin Calcium480$10,106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$19$135,900111 claims
Novo NordiskOzempic$66$72,14332 claims
Astellas Pharma US IncMyrbetriq$28$32,37239 claims
NovartisEntresto$16$16,15117 claims
AbbVieSynthroid$20$8,538100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →